Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biote Corp. (BTMD:NASDAQ), powered by AI.
Biote Corp. is currently trading at $2.19. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Biote Corp. on Alpha Lenz.
View Biote Corp.'s valuation metrics on Alpha Lenz.
“Biote Corp.'s ROE is -32.9%. Explore profitability and growth together.”
Ask for details →Biote Corp. operates in the healthcare sector as a life sciences company specializing in bioidentical hormone replacement therapy. The primary function of Biote Corp. is to provide comprehensive hormone optimization therapies designed to improve the quality of life for individuals experiencing hormonal imbalances and deficiencies. This is achieved through its innovative pellet therapy, a significant part of the hormone replacement treatment options available. Biote stands out in its field by offering not just the hormone therapies but also education for healthcare providers to ensure effective deployment of its solutions. By focusing on personalized health solutions, Biote Corp. impacts the healthcare industry, particularly in sectors related to wellness, anti-aging, and preventive medicine. Its approach aligns with the growing emphasis on personalized medicine, where treatment plans are tailored to individual patient needs. In the financial market, Biote Corp. plays a crucial role in expanding the portfolio of companies in the biotechnology and healthcare space, offering potential growth stories driven by the increasing demand for innovative health solutions. The company's efforts in hormone therapy contribute significantly to wellness and quality of life standards.
“Biote Corp.'s ROE is -32.9%. Explore profitability and growth together.”
Ask for details →Biote Corp. (ticker: BTMD) is a company listed on NASDAQ in the Healthcare sector (Medical Care Facilities). It has approximately 217 employees.
The current price is $2.19 with a P/E ratio of -x and P/B of -x.
ROE is -32.89% and operating margin is 18.50%. Annual revenue is $192M.